These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 32944474)

  • 41. Myasthenia gravis: the role of complement at the neuromuscular junction.
    Howard JF
    Ann N Y Acad Sci; 2018 Jan; 1412(1):113-128. PubMed ID: 29266249
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Myasthenia gravis induced by autoantibodies against MuSK].
    Shigemoto K; Konishi T; Ohta M
    Nihon Rinsho; 2008 Jun; 66(6):1149-54. PubMed ID: 18540361
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Myasthenia gravis.
    Silvestri NJ; Wolfe GI
    Semin Neurol; 2012 Jul; 32(3):215-26. PubMed ID: 23117946
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Muscle-Specific Receptor Tyrosine Kinase (MuSK) Myasthenia Gravis.
    Hurst RL; Gooch CL
    Curr Neurol Neurosci Rep; 2016 Jul; 16(7):61. PubMed ID: 27170368
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Emergency Tracheostomy Due to a Myasthenic Crisis in a Post-COVID Patient: Report of a Case.
    Valjarevic S; Lakicevic M; Jovanovic MB; Gavric J; Radaljac D
    SN Compr Clin Med; 2023; 5(1):148. PubMed ID: 37275565
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The agrin/muscle-specific kinase pathway: new targets for autoimmune and genetic disorders at the neuromuscular junction.
    Liyanage Y; Hoch W; Beeson D; Vincent A
    Muscle Nerve; 2002 Jan; 25(1):4-16. PubMed ID: 11754179
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Anti-MuSK antibodies in myasthenia gravis block binding of collagen Q to MuSK].
    Ohno K
    Rinsho Shinkeigaku; 2012; 52(11):1306-8. PubMed ID: 23196600
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical and scientific aspects of muscle-specific tyrosine kinase-related myasthenia gravis.
    Reddel SW; Morsch M; Phillips WD
    Curr Opin Neurol; 2014 Oct; 27(5):558-65. PubMed ID: 25159928
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Measurement of junctional acetylcholine receptors in myasthenia gravis: clinical correlates.
    Pestronk A; Drachman DB; Self SG
    Muscle Nerve; 1985; 8(3):245-51. PubMed ID: 4058469
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Genetic defects and disorders at the neuromuscular junction].
    Ohno K
    Brain Nerve; 2011 Jul; 63(7):669-78. PubMed ID: 21747136
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis.
    Zhang B; Tzartos JS; Belimezi M; Ragheb S; Bealmear B; Lewis RA; Xiong WC; Lisak RP; Tzartos SJ; Mei L
    Arch Neurol; 2012 Apr; 69(4):445-51. PubMed ID: 22158716
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Refractory bulbar and respiratory dysfunction in a young Chinese woman with seronegative, muscle-specific tyrosine kinase antibody-positive myasthenia gravis: response to cyclophosphamide and rituximab treatment.
    Lau AY; Chan AY; Mok VC
    Hong Kong Med J; 2011 Feb; 17(1):77-9. PubMed ID: 21282832
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Arecoline inhibits and destabilizes agrin-induced acetylcholine receptor cluster formation in C2C12 myotubes.
    Chang YF; Liu TY; Liu ST
    Food Chem Toxicol; 2013 Oct; 60():391-6. PubMed ID: 23933062
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Myasthenia gravis following human papillomavirus vaccination: a case report.
    Chung JY; Lee SJ; Shin BS; Kang HG
    BMC Neurol; 2018 Dec; 18(1):222. PubMed ID: 30593270
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Molecular mechanisms underlying the formation of neuromuscular junction].
    Higuchi O; Yamanashi Y
    Brain Nerve; 2011 Jul; 63(7):649-55. PubMed ID: 21747134
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Myasthenic symptoms in anti-low-density lipoprotein receptor-related protein 4 antibody-seropositive amyotrophic lateral sclerosis: two case reports.
    Takahashi H; Noto YI; Makita N; Kushimura-Okada Y; Ishii R; Tanaka A; Ohara T; Nakane S; Higuchi O; Nakagawa M; Mizuno T
    BMC Neurol; 2016 Nov; 16(1):229. PubMed ID: 27863479
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Update on Ocular Myasthenia Gravis.
    Smith SV; Lee AG
    Neurol Clin; 2017 Feb; 35(1):115-123. PubMed ID: 27886889
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Juvenile myasthenia gravis: three case reports and a literature review.
    Gadient P; Bolton J; Puri V
    J Child Neurol; 2009 May; 24(5):584-90. PubMed ID: 19406758
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Diagnostic utility of cortactin antibodies in myasthenia gravis.
    Illa I; Cortés-Vicente E; Martínez MÁ; Gallardo E
    Ann N Y Acad Sci; 2018 Jan; 1412(1):90-94. PubMed ID: 29068555
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Steroids induce acetylcholine receptors on cultured human muscle: implications for myasthenia gravis.
    Kaplan I; Blakely BT; Pavlath GK; Travis M; Blau HM
    Proc Natl Acad Sci U S A; 1990 Oct; 87(20):8100-4. PubMed ID: 2236023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.